Thapsigargin: key to new host-directed coronavirus antivirals?
Trends Pharmacol Sci
; 43(7): 557-568, 2022 07.
Article
in English
| MEDLINE | ID: covidwho-1796053
ABSTRACT
Despite the great success of vaccines that protect against RNA virus infections, and the development and clinical use of a limited number of RNA virus-specific drugs, there is still an urgent need for new classes of antiviral drugs against circulating or emerging RNA viruses. To date, it has proved difficult to efficiently suppress RNA virus replication by targeting host cell functions, and there are no approved drugs of this type. This opinion article discusses the recent discovery of a pronounced and sustained antiviral activity of the plant-derived natural compound thapsigargin against enveloped RNA viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV), and influenza A virus. Based on its mechanisms of action, thapsigargin represents a new prototype of compounds with multimodal host-directed antiviral activity.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Middle East Respiratory Syndrome Coronavirus
/
COVID-19 Drug Treatment
Type of study:
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Trends Pharmacol Sci
Year:
2022
Document Type:
Article
Affiliation country:
J.tips.2022.04.004
Similar
MEDLINE
...
LILACS
LIS